Physician profile
Ashok Bapat
NPI 1518960384
$9,971.61
in general payments reported to CMS, 2019-2025
64 companies · $32.13 in 2025
The $32.13 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,902 · 2020: $1,398 · 2021: $1,483 · 2022: $2,157 · 2025: $32.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $32.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $32.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,795.76 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,753.75 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $944.92 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $473.70 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $435.00 | 2019-2022 | |
| Pfizer INC. | $326.33 | 2019-2021 | |
| Genentech USA, INC. | $307.51 | 2019-2022 | |
| Gilead Sciences, INC. | $244.96 | 2019-2022 | |
| Celgene Corporation | $229.73 | 2019-2022 | |
| Aurobindo Pharma USA, INC. | $215.75 | 2019-2020 | |
| Amgen INC. | $214.94 | 2019-2022 | |
| Lilly USA, LLC | $185.88 | 2019-2020 | |
| Genzyme Corporation | $173.72 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $171.96 | 2019-2022 | |
| Incyte Corporation | $164.70 | 2019-2022 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Bapat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.